PDF(Pubmed)
Abstract：
UNASSIGNED: Disorders of the Gut-Brain Interaction (DGBIs) account for 50% of pediatric gastrointestinal (GI) consultations. Children with DGBIs have worse quality of life (QoL) than those with organic GI disorders such as inflammatory bowel disease and gastroesophageal reflux disease. Pediatric DGBIs patients, especially those with chronic abdominal pain (AP), have impaired QoL and increased psychological distress in the form of anxiety and depression. Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy has been shown to be effective in improving symptoms and functioning in children with DGBIs. The treatment\'s impact on these patients\' QoL is unknown.
UNASSIGNED: This prospective study evaluated changes in QoL, gastrointestinal symptoms, functional disability, somatization, global health, anxiety, and depression in patients aged 11-18 years who received PENFS therapy (IB-stim, NeurAxis, Versailles, IN) for treatment of pain related DGBIs, once a week for four consecutive weeks.
UNASSIGNED: This study included 31 patients with an average age of 15.7 years (SD = 2); 80.6% were female. After PENFS therapy, patients reported significant reductions in abdominal pain, nausea severity, functional disability, somatization, and anxiety from baseline to week 4 (p < 0.05). Parents reported significant improvement in their child\'s QoL regarding physical function, psychosocial function, and generic core scale scores (p < 0.05). Parents also noted reduced abdominal pain, functional disability, and somatization. Average scores on the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale significantly improved based on both patient and parent reports (p < 0.05). Our patients\' QoL was significantly lower than healthy controls at baseline and after treatment (p < 0.05).
UNASSIGNED: Our research demonstrates that PENFS significantly enhances the QoL of children suffering from pain-related DGBIs, in addition to improvement in GI symptoms, daily functioning, somatization, global health, and psychological comorbidities. These findings demonstrate the effectiveness of PENFS and its potential to alleviate the suffering of countless children.
UNASSIGNED: This prospective study evaluated changes in QoL, gastrointestinal symptoms, functional disability, somatization, global health, anxiety, and depression in patients aged 11-18 years who received PENFS therapy (IB-stim, NeurAxis, Versailles, IN) for treatment of pain related DGBIs, once a week for four consecutive weeks.
UNASSIGNED: This study included 31 patients with an average age of 15.7 years (SD = 2); 80.6% were female. After PENFS therapy, patients reported significant reductions in abdominal pain, nausea severity, functional disability, somatization, and anxiety from baseline to week 4 (p < 0.05). Parents reported significant improvement in their child\'s QoL regarding physical function, psychosocial function, and generic core scale scores (p < 0.05). Parents also noted reduced abdominal pain, functional disability, and somatization. Average scores on the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale significantly improved based on both patient and parent reports (p < 0.05). Our patients\' QoL was significantly lower than healthy controls at baseline and after treatment (p < 0.05).
UNASSIGNED: Our research demonstrates that PENFS significantly enhances the QoL of children suffering from pain-related DGBIs, in addition to improvement in GI symptoms, daily functioning, somatization, global health, and psychological comorbidities. These findings demonstrate the effectiveness of PENFS and its potential to alleviate the suffering of countless children.
摘要：
■肠脑相互作用（DGBIs）障碍占小儿胃肠道（GI）咨询的50％。患有DGBIs的儿童的生活质量（QoL）比患有器质性胃肠道疾病（例如炎症性肠病和胃食管反流病）的儿童差。儿童DGBIs患者，尤其是那些患有慢性腹痛（AP）的人，QoL受损，焦虑和抑郁形式的心理困扰增加。经皮神经电场刺激（PENFS）治疗已被证明可有效改善DGBIs儿童的症状和功能。治疗对这些患者QoL的影响尚不清楚。
■这项前瞻性研究评估了QoL的变化，胃肠道症状,功能性残疾，躯体化，全球健康,焦虑,接受PENFS治疗的11-18岁患者的抑郁症（IB-stim，NeurAxis,凡尔赛,IN）用于治疗疼痛相关的DGBIs，每周一次，连续四周。
■这项研究包括31名患者，平均年龄为15.7岁（SD=2）；80.6%为女性。PENFS治疗后,患者报告腹痛显著减轻，恶心的严重程度，功能性残疾，躯体化，从基线到第4周的焦虑（p<0.05）。父母报告说，他们孩子的QoL在身体功能方面有显著改善，社会心理功能,和通用核心量表评分(p<0.05)。父母还注意到腹痛减轻，功能性残疾，和躯体化。根据患者和家长报告，患者报告结果测量信息系统（PROMIS）全球健康量表的平均得分显着提高（p<0.05）。我们的患者在基线和治疗后的QoL显著低于健康对照组(p<0.05)。
■我们的研究表明，PENFS显著提高患有疼痛相关DGBIs的儿童的QoL，除了改善胃肠道症状，日常运作，躯体化，全球健康,和心理合并症。这些发现证明了PENFS的有效性及其减轻无数儿童痛苦的潜力。
■这项前瞻性研究评估了QoL的变化，胃肠道症状,功能性残疾，躯体化，全球健康,焦虑,接受PENFS治疗的11-18岁患者的抑郁症（IB-stim，NeurAxis,凡尔赛,IN）用于治疗疼痛相关的DGBIs，每周一次，连续四周。
■这项研究包括31名患者，平均年龄为15.7岁（SD=2）；80.6%为女性。PENFS治疗后,患者报告腹痛显著减轻，恶心的严重程度，功能性残疾，躯体化，从基线到第4周的焦虑（p<0.05）。父母报告说，他们孩子的QoL在身体功能方面有显著改善，社会心理功能,和通用核心量表评分(p<0.05)。父母还注意到腹痛减轻，功能性残疾，和躯体化。根据患者和家长报告，患者报告结果测量信息系统（PROMIS）全球健康量表的平均得分显着提高（p<0.05）。我们的患者在基线和治疗后的QoL显著低于健康对照组(p<0.05)。
■我们的研究表明，PENFS显著提高患有疼痛相关DGBIs的儿童的QoL，除了改善胃肠道症状，日常运作，躯体化，全球健康,和心理合并症。这些发现证明了PENFS的有效性及其减轻无数儿童痛苦的潜力。
